Navigation Links
Fixing the way to a Man’s Heart

The chances of men dieing from heart related disease’s are on the rise, taking a heavy toll of lives when compared to any other type of disease and often with little indication. //Research shows about one in every three men can expect to develop heart disease before age 60. Bad eating habits and no exercise lead to a build up of high cholesterol is a commonly known phenomenon. However, one may seem healthy but may not be.

Fortunately a lot of research is going into trying to find cures and preventions to this silent killer in men. New technological developments are allowing men to get diagnosed sooner and for the better.

A ten minute EBCT scan can detect even the smallest amounts of calcium deposits on artery walls. This helps patients to find out before they are in serious trouble whether they have high blood pressure and cholesterol problems or they have coronary disease.

Another commonly used method is using cardiac fingerprinting. It works on the principle of breaking down the cholesterol into 12 different components including seven LDLs -the so called bad cholesterol; three of these are large and are not very dangerous but four of them are very small. Hence they can prove to be very dangerous as they weasel their way into the artery much faster. With the cardiac fingerprinting patients can be help to frequently make checks on their condition and keep a firmer control on their health.

However, for those who are already suffering with the disease and have chest pain, researchers are studying adult stem cells as a way to help. Cells from a patient's own bone marrow is taken and inject into the heart to form new blood vessels.

Cardiologist Douglas W. Losordo, M.D., of Caritas St. Elizabeth's Medical Center/Tufts University School of Medicine in, Boston, says the treatment looks hopeful. "Several of the patients have actually experienced a significant reduction in their symptoms, so they're having fewer ch
'"/>




Page: 1 2

Related medicine news :

1. More and Better Management Is Key to Fixing the NHS
2. Mobile Phones Found To Reduce A Man’s Fertility by 30
3. Is Man’s Aggression Linked To His Finger
4. Sexy Images and Lingerie Challenge A Man’s Decision Making Skill
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Fixing the way Man Heart

Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 1KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 2KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 4KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 5KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 6Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 1Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 2Alzheimers Soars Global Focus Needed 3A Study 57748 1Alzheimers Soars Global Focus Needed 3A Study 57748 2Alzheimers Soars Global Focus Needed 3A Study 57748 3
Other Medicine Technology:Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10